ORCID Profile
0000-0002-6878-5196
Current Organisation
University of South Australia
Does something not look right? The information on this page has been harvested from data sources that may not be up to date. We continue to work with information providers to improve coverage and quality. To report an issue, use the Feedback Form.
Publisher: Bentham Science Publishers Ltd.
Date: 10-2023
DOI: 10.2174/1567201819666221010122413
Abstract: The current article mainly highlights mucoadhesive drug delivery with merits like the prolonged holding time at the action site and also provides a controlled rate of drug release for improved therapeutic outcomes. Moreover, mucosal delivery can eliminate problems of the conventional oral route, such as first pass metabolism as well as acid degradation. However, the eye has unique anatomy and physiology that can cause hindrance and challenges in comparison to the other organs of the body. Additionally, conventional delivery vehicles like solutions, suspensions, and ointments have many demerits such as rapid precorneal clearance, subject variability, drainage, and uncontrolled release from the dosage form. Therefore, novel pharmaceutical ophthalmic formulations like gels, nanosuspensions, nano-particles, liposomes, microemulsions, iontophoretic dosage forms, and ocuserts were tried and tested in the past few years for ophthalmic delivery. These novel delivery products provide enhanced solubility and bioavailability in a controlled manner to overcome conventional demerits. Here in this review, we have summarized the improvement of drug studies that are currently underway for eye drug carriers, along with stages and important aspects of novel drug delivery to the eye.
Publisher: Elsevier BV
Date: 09-2022
Publisher: Elsevier BV
Date: 11-2022
Publisher: Bentham Science Publishers Ltd.
Date: 06-2023
DOI: 10.2174/1874467215666220421130707
Abstract: Mycobacterium tuberculosis causes a contagious pulmonary disease with a high mortality rate in developing countries. However, the recommendation of DOTS (approved by WHO) was effective in treating tuberculosis, but nowadays resistance from the first line (MDR-TB) and the second line (XDR-TB) drugs is highly common. Whereas, the resistance is a result of factors like poor patient constancy due to the long duration of therapy and co-infection with HIV. The approval of bedaquiline under an accelerated program for the treatment of MDR-TB had revealed its effectiveness in clinical trials as a therapeutic novel molecule. BDQ selectively inhibits the ATP synthase of bacterium and reduces ATP production. Additionally, the poor pharmacokinetic properties had raised provocations in the MDR therapy, but the use of targeted drug delivery can solve the hurdles. While the preclinical and clinical studies included in this review are strongly suggesting the usefulness of BDQ in MDR-TB and XDR-TB, the repurposing of different drug classes in resistant TB is opening new opportunities to manage the disease conditions. In this review, we have summarized the ex les of pipeline drugs and repurposed molecules with preclinical formulation developments.
Publisher: Informa UK Limited
Date: 27-06-2023
No related grants have been discovered for Baljinder singh.